文献速递结核与非结核分枝杆菌医院感染防控

乌干达新生儿卡介苗对异源感染性疾病的非特异性影响:研究者盲法随机对照试验

BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2021-02-17

在乌干达Entebbe一家医院开展研究者盲法随机对照试验,560名健康新生儿随机分为出生时接种BCG组和6周龄延迟接种组。延迟组接种后(6-10周龄)两组无显著差异。出生时接种BCG抑制了TNF启动子组蛋白三甲基化在生后6周内的增加。

要点

  • 出生时接种BCG可降低新生儿期非结核感染性疾病的发病率。
  • BCG对异源感染的保护作用可能与训练免疫的表观遗传调控有关。
  • 在6周龄延迟接种BCG后,两组非结核感染性疾病发病率无显著差异。

核心结论

  • 出生时接种BCG可预防新生儿期非结核感染性疾病,此外还具有结核特异性效应。
  • 在高死亡率地区优先在出生第一天接种BCG可能通过减少全因感染性疾病发病率和死亡率带来显著公共卫生效益。

研究设计与样本

  • 研究者盲法、随机对照试验,在乌干达Entebbe一家医院开展。
  • 560名参与者出生时招募,按1:1随机分配至出生时接种标准剂量BCG(BCG-Danish)组(n=280)或6周龄接种组(n=280)。
  • 随机化采用计算机生成、区组大小24、按性别分层;研究者和临床医生设盲,家长不设盲。
  • 临床随访至10周龄,参与者提供血样参与三项免疫学子研究。
  • 主要临床结局为医生诊断的非结核感染性疾病发病率;主要免疫学结局包括TNF、IL6和IL1B启动子区域组蛋白三甲基化、异源刺激后TNF、IL-6、IL-1β、IL-10和IFNγ的离体产生、转铁蛋白饱和度和铁调素水平。

临床怎么用

  • 在高死亡率地区,可考虑优先在出生第一天接种BCG以降低新生儿期非结核感染性疾病发病率。
  • BCG的非特异性保护效应提示其公共卫生效益可能超出结核预防。

局限性

  • 研究在乌干达单一医院开展,外部推广性需进一步验证。
  • 家长未设盲,可能影响临床结局的报告。
  • 随访仅至10周龄,长期效应未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trials done in infants with low birthweight in west Africa suggest that BCG vaccination reduces all-cause mortality in the neonatal period, probably because of heterologous protection against non-tuberculous infections. This study investigated whether BCG alters all-cause infectious disease morbidity in healthy infants in a different high-mortality setting, and explored whether the changes are mediated via trained innate immunity. METHODS: This was an investigator-blind, randomised, controlled trial done at one hospital in Entebbe, Uganda. Infants who were born unwell (ie, those who were not well enough to be discharged directly home from the labour ward because they required medical intervention), with major congenital malformations, to mothers with HIV, into families with known or suspected tuberculosis, or for whom cord blood samples could not be taken, were excluded from the study. Any other infant well enough to be discharged directly from the labour ward was eligible for inclusion, with no limitation on gestational age or birthweight. Participants were recruited at birth and randomly assigned (1:1) to receive standard dose BCG 1331 (BCG-Danish) on the day of birth or at age 6 weeks (computer-generated randomisation, block sizes of 24, stratified by sex). Investigators and clinicians were masked to group assignment; parents were not masked. Participants were clinically followed up to age 10 weeks and contributed blood samples to one of three immunological substudies. The primary clinical outcome was physician-diagnosed non-tuberculous infectious disease incidence. Primary immunological outcomes were histone trimethylation at the promoter region of TNF, IL6, and IL1B; ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation; and transferrin saturation and hepcidin levels. All outcomes were analysed in the modified intention-to-treat population of all randomly assigned participants except those whose for whom consent was withdrawn. This trial is registered with the International Standard Randomised Controlled Trial Number registry (#59683017). FINDINGS: Between Sept 25, 2014, and July 31, 2015, 560 participants were enrolled and randomly assigned to receive BCG at birth (n=280) or age 6 weeks (n=280). 12 participants assigned to receive BCG at birth and 11 participants assigned to receive BCG at age 6 weeks were withdrawn from the study by their parents shortly after randomisation and were not included in analyses. During the first 6 weeks of life before the infants in the delayed vaccination group received BCG vaccination, physician-diagnosed non-tuberculous infectious disease incidence was lower in infants in the BCG at birth group than in the delayed group (98 presentations in the BCG at birth group vs 129 in the delayed BCG group; hazard ratio [HR] 0·71 [95% CI 0·53-0·95], p=0·023). After BCG in the delayed group (ie, during the age 6-10 weeks follow-up), there was no significant difference in non-tuberculous infectious disease incidence between the groups (88 presentations vs 76 presentations; HR 1·10 [0·87-1·40], p=0·62). BCG at birth inhibited the increase in histone trimethylation at the TNF promoter in peripheral blood mononuclear cells occurring in the first 6 weeks of life. H3K4me3 geometric mean fold-increases were 3·1 times lower at the TNF promoter (p=0·018), 2·5 times lower at the IL6 promoter (p=0·20), and 3·1 times lower at the IL1B promoter (p=0·082) and H3K9me3 geometric mean fold-increases were 8·9 times lower at the TNF promoter (p=0·0046), 1·2 times lower at the IL6 promoter (p=0·75), and 4·6 times lower at the IL1B promoter (p=0·068), in BCG-vaccinated (BCG at birth group) versus BCG-naive (delayed BCG group) infants. No clear effect of BCG on ex-vivo production of TNF, IL-6, IL-1β, IL-10, and IFNγ after heterologous stimulation, or transferrin saturation and hepcidin concentration, was detected (geometric mean ratios between 0·68 and 1·68; p≥0·038 for all comparisons). INTERPRETATION: BCG vaccination protects against non-tuberculous infectious disease during the neonatal period, in addition to having tuberculosis-specific effects. Prioritisation of BCG on the first day of life in high-mortality settings might have significant public-health benefits through reductions in all-cause infectious morbidity and mortality. FUNDING: Wellcome Trust. TRANSLATIONS: For the Luganda and Swahili translations of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021. PMID: 33609457. doi:10.1016/S1473-3099(20)30653-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。